Effect of CYP2C19, UGT1A8, and UGT2B7 on valproic acid clearance in children with epilepsy: a population pharmacokinetic model
- 1 Downloads
Valproic acid (VPA) is an important drug in seizure control with great inter-individual differences in metabolism and treatment effect. This study aims to identify the effects of genetic variants on VPA clearance in a population pharmacokinetic (popPK) model in children with epilepsy.
A total of 325 VPA plasma concentrations from 290 children with epilepsy were used to develop the popPK model by using the nonlinear mixed-effects modeling method. The one-compartment model was established to describe the pharmacokinetics of VPA. Twelve single nucleotide polymorphisms involved in the pharmacokinetics of VPA were identified by MassARRAY system and their effects on VPA clearance were evaluated.
In the two final popPK models, inclusion of a combined genotype of four variants (rs1042597, rs28365062, rs4986893, and rs4244285), total daily dose (TDD), and body surface area (BSA) significantly reduced inter-individual variability for clearance over the base model. The inter-individual clearance equals to 0.73 × (TDD/628.92)0.59 × eUGT-CYP for TDD included model and 0.70 × (BSA/0.99)0.57 × eUGT-CYP for BSA included model. The precision of all parameters were acceptable (relative standard error < 32.81%). Bootstrap and visual predictive check results indicated that both two final popPK models were stable with acceptable predictive ability.
TDD, BSA, and genotype might affect VPA clearance in children. The popPK models may be useful for dosing adjustment in children on VPA therapy.
KeywordsValproic acid Uridine diphosphate glucuronosyltransferase Cytochrome P450 family 2 subfamily C member 19 Clearance Children Population pharmacokinetic model Nonlinear mixed-effects modeling
Thanks are given to our patients.
Compliance with ethical standards
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
Conflict of interest
The authors declare that they have no conflict of interest.
- 5.Lin WW, Jiao Z, Wang CL, Wang HY, Ma CL, Huang PF, Guo XZ, Liu YW (2015) Population pharmacokinetics of valproic acid in adult Chinese epileptic patients and its application in an individualized dosage regimen. Ther Drug Monit 37:76–83. https://doi.org/10.1097/ftd.0000000000000100 CrossRefPubMedGoogle Scholar
- 6.Ding J, Wang Y, Lin W, Wang C, Zhao L, Li X, Zhao Z, Miao L, Jiao Z (2015) A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation. Clin Pharmacokinet 54:305–317. https://doi.org/10.1007/s40262-014-0212-8 CrossRefPubMedGoogle Scholar
- 10.Nakashima H, Oniki K, Nishimura M, Ogusu N, Shimomasuda M, Ono T, Matsuda K, Yasui-Furukori N, Nakagawa K, Ishitsu T, Saruwatari J (2015) Determination of the optimal concentration of valproic acid in patients with epilepsy: a population pharmacokinetic-pharmacodynamic analysis. PLoS One 10:e0141266. https://doi.org/10.1371/journal.pone.0141266 CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Ogusu N, Saruwatari J, Nakashima H, Noai M, Nishimura M, Deguchi M, Oniki K, Yasui-Furukori N, Kaneko S, Ishitsu T, Nakagaswa K (2014) Impact of the superoxide dismutase 2 Val16Ala polymorphism on the relationship between valproic acid exposure and elevation of gamma-glutamyltransferase in patients with epilepsy: a population pharmacokinetic-pharmacodynamic analysis. PLoS One 9:e111066. https://doi.org/10.1371/journal.pone.0111066 CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Jiang D, Bai X, Zhang Q, Lu W, Wang Y, Li L, Müller M (2009) Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling. Eur J Clin Pharmacol 65:1187–1193. https://doi.org/10.1007/s00228-009-0712-x CrossRefPubMedGoogle Scholar
- 15.Bondareva IB, Jelliffe RW, Sokolov AV, Tischenkova IF (2004) Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage. J Clin Pharm Ther 29:105–120. https://doi.org/10.1111/j.1365-2710.2003.00538.x CrossRefPubMedGoogle Scholar
- 18.Tan L, Yu JT, Sun YP, Ou JR, Song JH, Yu Y (2010) The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. Clin Neurol Neurosurg 112:320–323. https://doi.org/10.1016/j.clineuro.2010.01.002 CrossRefPubMedGoogle Scholar
- 24.Feng W, Mei S, Zhu L, Yu Y, Yang W, Gao B, Wu X, Zhao Z, Fang F (2016) Effects of UGT1A6 and GABRA1 on standardized valproic acid plasma concentrations and treatment effect in children with epilepsy in China. Ther Drug Monit 38:738–743. https://doi.org/10.1097/ftd.0000000000000337 CrossRefPubMedGoogle Scholar
- 25.Shintani M, Ieiri I, Inoue K, Mamiya K, Ninomiya H, Tashiro N, Higuchi S, Otsubo K (2001) Genetic polymorphisms and functional characterization of the 5′-flanking region of the human CYP2C9 gene: in vitro and in vivo studies. Clin Pharmacol Ther 70:175–182. https://doi.org/10.1067/mcp.2001.117367 CrossRefPubMedGoogle Scholar
- 26.Buetow KH, Edmonson M, MacDonald R et al (2001) High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proc Natl Acad Sci U S A 98:581–584. https://doi.org/10.1073/pnas.021506298 CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Mei S, Li X, Jiang X, Yu K, Lin S, Zhao Z (2018) Population pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma. J Pharm Sci. https://doi.org/10.1016/j.xphs.2018.01.004
- 36.Haas DW, Kwara A, Richardson DM, Baker P, Papageorgiou I, Acosta EP, Morse GD, Court MH (2014) Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes. J Antimicrob Chemother 69:2175–2182. https://doi.org/10.1093/jac/dku110 CrossRefPubMedPubMedCentralGoogle Scholar
- 44.Kirchheiner J, Klein C, Meineke I, Sasse J, Zanger UM, Mürdter TE, Roots I, Brockmöller J (2003) Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 13:619–626. https://doi.org/10.1097/01.fpc.0000054125.14659.d0 CrossRefPubMedGoogle Scholar
- 45.Kiyotani K, Yamazaki H, Fujieda M, Iwano S, Matsumura K, Satarug S, Ujjin P, Shimada T, Guengerich FP, Parkinson A, Honda G, Nakagawa K, Ishizaki T, Kamataki T (2003) Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9). Pharmacogenetics 13:689–695. https://doi.org/10.1097/01.fpc.0000054136.14659.be CrossRefPubMedGoogle Scholar
- 46.Yoshida R, Nakajima M, Nishimura K, Tokudome S, Kwon JT, Yokoi T (2003) Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin Pharmacol Ther 74:69–76. https://doi.org/10.1016/s0009-9236(03)00090-0 CrossRefPubMedGoogle Scholar